Moonlight Therapeutics has initiated a Phase 1 clinical trial for MOON101, a patch-type peanut allergy treatment that uses microneedle skin stamps to deliver peanut extract. This development signals a potential shift in allergy immunotherapy delivery, relevant for medical aesthetics distributors and clinics exploring transdermal drug delivery systems and patient-friendly treatment options.
Clinical trial details
The Phase 1 study will evaluate the safety and tolerability of MOON101 in 40 participants aged 4 to 55 with peanut allergies. The trial is expected to run until December 2027. Moonlight Therapeutics, based in the United States, is developing this patch as a home-use alternative to existing oral immunotherapy.
Market signal: Oral immunotherapy struggles
In January 2020, the U.S. FDA approved Palforzia (peanut allergen powder) as the first peanut allergy treatment for patients aged 4 to 17. However, daily oral dosing requirements have limited patient adherence and commercial success. Palforzia's peak annual sales were projected to exceed $1 billion, but it reported only $165 million in 2022 and will cease distribution on July 31, 2025.
Sourcing context: Patch technology opportunity
The patch format addresses key drawbacks of oral immunotherapy—daily dosing burden and low compliance. MOON101 uses microneedle skin stamps to deliver controlled amounts of peanut extract through the skin, enabling convenient at-home use. If successful, this approach could unlock the projected $1 billion-plus market that Palforzia failed to capture.
What buyers should watch
Distributors and clinics should monitor MOON101's Phase 1 results for safety and tolerability data. The patch delivery system may offer a new category for medical aesthetics practices already familiar with transdermal technologies. Success could create demand for complementary skincare products and application devices, opening supply-chain opportunities for OEM partners.
Source: Read the original report | Published: June 08, 2026